Capital Group Investment Management PTE. LTD. Has $10.30 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

Capital Group Investment Management PTE. LTD. lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 26,286 shares of the pharmaceutical company’s stock after selling 1,213 shares during the period. Vertex Pharmaceuticals comprises about 1.7% of Capital Group Investment Management PTE. LTD.’s holdings, making the stock its 13th biggest position. Capital Group Investment Management PTE. LTD.’s holdings in Vertex Pharmaceuticals were worth $10,295,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Vertex Pharmaceuticals by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock valued at $9,484,293,000 after acquiring an additional 243,088 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 5,928,747 shares of the pharmaceutical company’s stock worth $2,627,135,000 after purchasing an additional 166,987 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Vertex Pharmaceuticals by 10.7% during the second quarter. Alliancebernstein L.P. now owns 4,378,320 shares of the pharmaceutical company’s stock valued at $1,949,228,000 after purchasing an additional 424,808 shares during the period. Loomis Sayles & Co. L P raised its stake in shares of Vertex Pharmaceuticals by 1.7% in the second quarter. Loomis Sayles & Co. L P now owns 3,813,378 shares of the pharmaceutical company’s stock valued at $1,697,716,000 after purchasing an additional 65,047 shares in the last quarter. Finally, Norges Bank bought a new position in Vertex Pharmaceuticals in the second quarter worth $1,593,974,000. 90.96% of the stock is currently owned by institutional investors.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: RAINIER Phase 3 interim analysis met the primary endpoint and all secondary endpoints at Week 36, with treated patients showing the intended benefit versus placebo — a major validation step for povetacicept in IgA nephropathy. Vertex Announces Positive Week 36 Interim Analysis Results (BusinessWire)
• Positive Sentiment: Management plans an FDA filing for povetacicept by March, accelerating the regulatory timeline and shortening the path to potential commercialization if final data and review go smoothly. Vertex Stock Surges After Positive Kidney Disease Trial Results (Blockonomi)
• Positive Sentiment: Analysts have reiterated and strengthened bullish views — William Blair’s Myles Minter reiterated a Buy and highlighted increased confidence in povetacicept’s commercial potential, supporting upside to consensus models. Analyst Confidence Boosts Buy Thesis (TipRanks)
• Positive Sentiment: Market reaction: shares rallied in extended trading after the release; coverage notes the asset was acquired in a prior multibillion-dollar deal and is viewed as having “best‑in‑class” potential in a competitive kidney disease market. Vertex Kidney Drug Hits Mark in Late-Stage Study (BioPharmaDive)
• Neutral Sentiment: The result cited is an interim analysis of an ongoing trial — final RAINIER readout, full safety dataset, and regulatory review still lie ahead, so approval and peak sales remain subject to execution and FDA assessment. Press Release / Interim Analysis Details (Yahoo Finance)

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $460.87 on Tuesday. The company’s fifty day moving average is $467.50 and its 200-day moving average is $435.79. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68. The company has a market capitalization of $117.07 billion, a PE ratio of 30.06 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. During the same quarter last year, the business earned $3.98 EPS. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Evercore lifted their price target on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $590.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Oppenheimer upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 target price on the stock in a research report on Friday, February 13th. Leerink Partners upped their target price on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research note on Monday, December 29th. Finally, Scotiabank increased their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. Twenty-two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $542.00.

Insider Activity

In other news, EVP Jonathan Biller sold 945 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $459,600.75. Following the transaction, the executive vice president directly owned 13,659 shares of the company’s stock, valued at $6,643,054.65. The trade was a 6.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Amit Sachdev sold 1,846 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $897,802.10. Following the sale, the executive vice president owned 55,570 shares in the company, valued at approximately $27,026,469.50. This trade represents a 3.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 91,156 shares of company stock valued at $42,845,497. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.